A. Hauschild

发表

Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networks.

A. Enk, J. Winkler, R. Maron, 2019, European journal of cancer.

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

A. Hauschild, P. Ascierto, J. Larkin, 2017, European journal of cancer.

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

A. Hauschild, C. Blank, W. Miller, 2012, The Lancet.

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

A. Hauschild, D. Schadendorf, K. Flaherty, 2011, The New England journal of medicine.

Surgical Standards in the Primary Care of Melanoma Patients

A. Hauschild, S. Lischner, F. Rosien, 2003, Oncology Research and Treatment.

Fear of cancer progression in patients with stage IA malignant melanoma

A. Hauschild, D. Schadendorf, K. Kähler, 2018, European journal of cancer care.

Basal cell carcinoma-treatments for the commonest skin cancer.

C. Berking, A. Hauschild, G. Mast, 2014, Deutsches Arzteblatt international.

S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 1: Epidemiology, Genetics and Diagnosis

M. Weichenthal, A. Hauschild, A. Blum, 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

To excise or not: impact of MelaFind on German dermatologists’ decisions to biopsy atypical lesions

M. Weichenthal, A. Hauschild, D. Scharfstein, 2014, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Improved overall survival in melanoma with combined dabrafenib and trametinib.

A. Hauschild, D. Schadendorf, K. Flaherty, 2015, The New England journal of medicine.

Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma.

A. Hauschild, D. Schadendorf, W. Stolz, 2008, Melanoma research.

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

J. Utikal, A. Hauschild, D. Schadendorf, 2014, The New England journal of medicine.

Deep neural networks are superior to dermatologists in melanoma image classification.

Tim Holland-Letz, Achim Hekler, Jochen S. Utikal, 2019, European journal of cancer.

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Axel Hoos, Alessandro Testori, Axel Hauschild, 2011, The New England journal of medicine.

Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma

A. Hauschild, D. Schadendorf, S. Ugurel, 2008, Melanoma research.

Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma

A. Hauschild, R. Gonzalez, A. Eggermont, 2007 .

Up‐to‐date results on survival of patients with melanoma in Germany

A. Hauschild, H. Brenner, L. Jansen, 2012, The British journal of dermatology.

Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma .

A. Hauschild, K. Flaherty, P. Ascierto, 2012 .

An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).

A. Hauschild, C. Blank, W. Miller, 2013 .

Who benefits most from adjuvant interferon treatment for melanoma?

A. Hauschild, H. Pehamberger, P. Ascierto, 2015, American journal of therapeutics.

A. Hauschild, F. Egberts, A. Heinz, 2011, Journal of immunotherapy.

Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.

M. Weichenthal, C. Berking, A. Hauschild, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma.

A. Hauschild, D. Schadendorf, V. Sondak, 2010, European journal of cancer.

Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.

M. Weichenthal, A. Hauschild, D. Schadendorf, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Utility of adjuvant systemic therapy in melanoma

A. Hauschild, A. Eggermont, A. Testori, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting.

A. Hauschild, D. Schadendorf, W. Stolz, 2008, Melanoma research.

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

A. Hauschild, R. Dummer, A. Eggermont, 2008, The Lancet.

Interdisciplinary management recommendations for toxicity associated with interferon‐alfa therapy

A. Hauschild, K. Kähler, M. Fluck, 2008, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis.

M. Weichenthal, A. Hauschild, D. Schadendorf, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Therapy in Melanoma

M. Weichenthal, A. Hauschild, P. Mohr, 1998, Oncology Research and Treatment.

Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG “GERMELATOX survey”) versus melanoma recurrence to quantify patients’ relative values for adjuvant therapy

J. Utikal, A. Hauschild, D. Schadendorf, 2016, Medicine.

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

A. Hauschild, P. Ascierto, R. Dummer, 2016, The New England journal of medicine.

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022.

A. Lallas, I. Zalaudek, A. Hauschild, 2022, European journal of cancer.

Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.

I. Zalaudek, A. Hauschild, J. Malvehy, 2019, European journal of cancer.

Telomerase activity in melanocytic lesions: A potential marker of tumor biology.

A. Hauschild, R. Parwaresch, G. Krupp, 2000, The American journal of pathology.

[Sentinel lymph node biopsy].

A. Hauschild, 2005, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

Diagnosis and treatment of basal cell carcinoma: European consensusebased interdisciplinary guidelines

I. Zalaudek, A. Hauschild, J. Malvehy, 2019 .

Melanoma early detection and awareness: how countries developing melanoma awareness programs could benefit from melanoma-proficient countries.

A. Hauschild, P. Hersey, L. Bastholt, 2015, American journal of therapeutics.

The Impact of Multispectral Digital Skin Lesion Analysis on German Dermatologist Decisions to Biopsy Atypical Pigmented Lesions with Clinical Characteristics of Melanoma.

A. Hauschild, D. Rigel, R. Winkelmann, 2015, The Journal of clinical and aesthetic dermatology.

Guideline Implementation in Merkel Cell Carcinoma: An Example of a Rare Disease

A. Hauschild, K. Kähler, J. Becker, 2006 .

Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.

A. Hauschild, R. Dummer, K. Peris, 2018, European Journal of Cancer.

AnalysisofDermatologic Events inVemurafenib-TreatedPatients WithMelanoma

Patrícia, A. Hauschild, D. Schadendorf, 2013 .

Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG.

J. Utikal, A. Hauschild, D. Schadendorf, 2018, European journal of cancer.

Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion.

A. Hauschild, H. Lipp, F. Lordick, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Double Trouble: Immunotherapy Doublets in Melanoma-Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma.

A. Hauschild, G. Long, J. Mehnert, 2022, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.

A. Hauschild, K. Kähler, P. Ascierto, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up

J. Utikal, A. Hauschild, D. Schadendorf, 2013, Clinical Cancer Research.

Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma

A. Hauschild, J. Kirkwood, P. Hersey, 2010, Clinical Cancer Research.

Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma.

A. Hauschild, K. Kähler, P. Schlag, 2007, European Journal of Surgical Oncology.

Repeatable acute rhabdomyolysis with multiple organ dysfunction because of interferon α and dacarbazine treatment in metastatic melanoma

A. Hauschild, S. Lischner, E. Christophers, 2001, The British journal of dermatology.

FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th2011”

A. Hauschild, K. Flaherty, P. Ascierto, 2012, Journal of Translational Medicine.

Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response.

A. Hauschild, K. Kähler, Sarah Schäfer, 2021, European journal of cancer.

Artificial Intelligence and Its Effect on Dermatologists’ Accuracy in Dermoscopic Melanoma Image Classification: Web-Based Survey Study

Roman C. Maron, R. Maron, M. Weichenthal, 2020, Journal of medical Internet research.

Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG)

A. Hauschild, D. Schadendorf, J. Becker, 2003, Melanoma research.

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study

A. Hauschild, D. Schadendorf, R. Gonzalez, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

1092PDAN UPDATE ON OVERALL SURVIVAL (OS) AND FOLLOW-ON THERAPIES IN BREAK-3, A PHASE III, RANDOMIZED TRIAL: DABRAFENIB (D) VS. DACARBAZINE (DTIC) IN PATIENTS (PTS) WITH BRAF V600E MUTATION-POSITIVE METASTATIC MELANOMA (MM).

A. Hauschild, C. Blank, V. Chiarion Sileni, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma

A. Hauschild, D. Schadendorf, R. Dummer, 2016 .

Epidemiology of invasive cutaneous melanoma

A. Hauschild, A. Eggermont, R. MacKie, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

A. Hauschild, R. Dummer, M. Gore, 2008 .

European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment.

I. Zalaudek, A. Hauschild, J. Malvehy, 2020, European journal of cancer.

Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy.

A. Hauschild, D. Schadendorf, K. Flaherty, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diabetes Mellitus in Cancer Patients Treated with Combination Interleukin 2 and α-Interferon

A. Hauschild, R. Figlin, E. Christophers, 1995 .

Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022.

A. Lallas, I. Zalaudek, A. Hauschild, 2022, European journal of cancer.

Installation of a network for patients with congenital melanocytic nevi in German‐speaking countries

A. Hauschild, H. Breuninger, H. Hamm, 2008, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.

A. Hauschild, P. Ascierto, R. Dummer, 2017, European journal of cancer.

[Cutaneous lymphoma].

A. Hauschild, R. Dummer, W. Sterry, 1996, Deutsche Medizinische Wochenschrift.

Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient.

A. Hauschild, F. Egberts, P. Lorigan, 2009, Melanoma research.

Treatment and side effect management of CTLA‐4 antibody therapy in metastatic melanoma

A. Hauschild, K. Kähler, 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.

A. Hauschild, D. Schadendorf, B. Schilling, 2010, Seminars in oncology.

[Skin changes as a result of targeted therapies in oncology patients: cutaneous side effects of targeted therapies in oncology patients].

A. Hauschild, K. Kähler, 2009, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis

A. Hauschild, D. Schadendorf, I. Lowy, 2021, Journal for ImmunoTherapy of Cancer.

Co-expression of NGF and PD-L1 on tumor-associated immune cells in the microenvironment of Merkel cell carcinoma

M. Weichenthal, A. Hauschild, U. Wehkamp, 2018, Journal of Cancer Research and Clinical Oncology.

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

A. Hauschild, D. Schadendorf, K. Flaherty, 2019, The New England journal of medicine.

Intraoral lesions associated with sebaceous nevus syndrome

A. Hauschild, P. Warnke, I. Springer, 2006, Journal of cutaneous pathology.

The sebaceous nevus as part of the Schimmelpenning–Feuerstein–Mims Syndrome – an obvious phacomatosis first documented in 1927

A. Hauschild, P. Warnke, I. Springer, 2003, Journal of cutaneous pathology.

Eruptive vellus hair cysts and steatocystoma multiplex. Variants of one entity?

A. Hauschild, E. Christophers, P. Kiene, 1996, The British journal of dermatology.

Coincident PTCH and BRCA1 germline mutations in a patient with nevoid basal cell carcinoma syndrome and familial breast cancer.

A. Hauschild, G. Reifenberger, M. Kiechle, 2001, Journal of Investigative Dermatology.

[Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma].

A. Hauschild, F. Mornex, B. Nguyen, 2003, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma

A. Hauschild, B. Bui, F. Mornex, 2003, Melanoma research.

Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma

A. Hauschild, A. Ribas, C. Punt, 2008 .

Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma

J. Utikal, C. Berking, A. Hauschild, 2015, Journal of Translational Medicine.

Tropomyosin Receptor Kinase A Expression on Merkel Cell Carcinoma Cells

A. Hauschild, U. Wehkamp, F. Egberts, 2017, JAMA dermatology.

Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centers

A. Hauschild, R. Gutzmer, A. Wollenberg, 2012, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Skin Toxicities due to Biotherapy

A. Hauschild, M. Lacouture, K. Kaehler, 2013 .

Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease

M. Weichenthal, A. Hauschild, K. Kähler, 2016, Journal of immunotherapy.

Immunotherapy: Combined immunotherapy—a new standard in metastatic melanoma?

A. Hauschild, C. Garbe, 2015, Nature Reviews Clinical Oncology.

Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials

A. Hauschild, D. Schadendorf, P. Ascierto, 2014, Journal of Translational Medicine.

Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial.

M. Weichenthal, C. Berking, A. Hauschild, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

EORTC 18991: Long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial

A. Hauschild, M. Gore, A. Eggermont, 2007 .

Phase I/II study with trabedersen (AP 12009) monotherapy for the treatment of patients with advanced pancreatic cancer, malignant melanoma, and colorectal carcinoma.

A. Enk, A. Hauschild, C. Garbe, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Therapy in Melanoma

M. Weichenthal, A. Hauschild, P. Mohr, 1998, Oncology Research and Treatment.

Increased risk of immune checkpoint inhibitor-induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?

A. Hauschild, K. Kähler, A. Bohne, 2020, European Journal of Cancer.

Could controlling occult cytomegalovirus reactivation with prophylactic valganciclovir prevent immune checkpoint blockade-Related complications?

A. Hauschild, 2021, European Journal of Cancer.

A. Hauschild, D. Schadendorf, R. Dummer, 2016, European journal of cancer.

Discrimination between immunoaccessory and phagocytic monocytes/macrophages of the skin in paraffin‐embedded tissue by the monoclonal antibody Ki‐M1P

A. Hauschild, H. Radzun, W. Sterry, 1993, The British journal of dermatology.

Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma

A. Hauschild, K. Flaherty, P. Ascierto, 2011 .

Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients.

A. Hauschild, F. Egberts, U. Reinhold, 2020, European Journal of Cancer.

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma

A. Hauschild, D. Schadendorf, R. Dummer, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk evaluation in cutaneous melanoma patients undergoing lymph node dissection: impact of POSSUM.

A. Hauschild, F. Egberts, C. Schafmayer, 2011, Annals of the Royal College of Surgeons of England.

Remarkable remission of a follicular lymphoma treated with rituximab and polychemotherapy (CHOP)

A. Hauschild, S. Lischner, E. Stockfleth, 2003, Clinical and experimental dermatology.

Short German guidelines: Malignant melanoma

A. Hauschild, D. Schadendorf, W. Stolz, 2008, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

21. Miscellaneous Reactions

A. Hauschild, M. Lacouture, K. Kaehler, 2013 .

Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.

A. Hauschild, S. Arron, C. Rudin, 2015, Journal of the American Academy of Dermatology.

Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.

A. Hauschild, P. Ascierto, R. Dummer, 2015, The Lancet. Oncology.

Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors.

A. Hauschild, D. Schadendorf, F. Egberts, 2010, The Journal of investigative dermatology.

Primary Extracutaneous Malignant Melanoma: A Comprehensive Review with Emphasis on Treatment

A. Hauschild, D. Schadendorf, A. Thoelke, 2004, Oncology Research and Treatment.

Cutaneous Gamma-Delta T-Cell Lymphoma Successfully Treated With Brentuximab Vedotin

A. Hauschild, K. Kähler, L. V. Maul, 2016 .

[Systemic treatment of melanoma. Current clinical trials].

A. Hauschild, W. Tilgen, K. Rass, 2008, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?

A. Hauschild, Axel Hauschild, 2009, Current oncology.

Maintenance therapy in cutaneous T-cell lymphoma: who, when, what?

A. Hauschild, R. Dummer, S. Whittaker, 2007, European journal of cancer.

Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self‐adhesive 5‐aminolaevulinic acid patch

A. Hauschild, H. Gollnick, S. Karrer, 2009, Experimental dermatology.

Formalin-resistant leukocyte surface antigens in the diagnosis of cutaneous malignant lymphomas.

A. Hauschild, W. Sterry, 1989, The American journal of pathology.

Cancer Therapy : Clinical Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermato fi brosarcoma Protuberans : AMulticenter Phase II DeCOG Trial with Long-term Follow-up

J. Utikal, A. Hauschild, D. Schadendorf, 2014 .

Malignant Melanoma and Wiedemann-Beckwith Syndrome in Childhood

A. Hauschild, F. Egberts, R. Siebert, 2010, Klinische Padiatrie.

The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians

J. Utikal, A. Hauschild, D. Schadendorf, 2018, Oncotarget.

Clinical evaluation of 5-S-cysteinyldopa testing using a new and optimized detection system as a tumour marker for malignant melanoma

A. Hauschild, E. Stockfleth, T. Meyer, 2002, Melanoma research.

Elevated MIA serum levels are of relevance for management of metastasized malignant melanomas: results of a German multicenter study.

A. Hauschild, D. Schadendorf, W. Stolz, 2000, Journal of Investigative Dermatology.

Checkpoint inhibitors: a new standard of care for advanced Merkel cell carcinoma?

A. Hauschild, D. Schadendorf, 2016, The Lancet. Oncology.

Melanocytic schwannoma of the cutaneous and subcutaneous tissues: three cases and a review of the literature

A. Hauschild, P. Russo, T. Kreusch, 2008, Melanoma research.

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.

A. Hauschild, D. Schadendorf, R. Dummer, 2020, The New England journal of medicine.

Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease.

A. Hauschild, D. Schadendorf, R. Dummer, 2014, European journal of cancer.

Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient’s choice: a multicentre Dermatologic Cooperative Oncology Group trial

M. Weichenthal, A. Hauschild, D. Schadendorf, 2011, Melanoma research.

Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment

J. Utikal, C. Berking, A. Hauschild, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma.

A. Hauschild, D. Schadendorf, S. Ugurel, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-Term Outcomes in Patients With BRAF V 600-Mutant Metastatic Melanoma Receiving Dabrafenib Monotherapy : Analysis From Phase 2 and 3 Clinical Trials

A. Hauschild, D. Schadendorf, P. Ascierto, 2021 .

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma

C. Berking, A. Hauschild, D. Schadendorf, 2019, Oncotarget.

Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.

A. Hauschild, R. Dummer, M. Lacouture, 2008, European Journal of Cancer.

Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma.

A. Hauschild, L. Heinzerling, G. Schuler, 2016, European journal of cancer.

Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients.

A. Hauschild, W. Brenner, E. Henze, 1999, Melanoma research.

Effective and Tolerable Treatment of Advanced Basal Cell Carcinoma With Vismodegib Despite Renal Insufficiency.

A. Hauschild, K. Kähler, L. V. Maul, 2016, JAMA dermatology.

Factors Predictive of the Status of Sentinel Lymph Nodes in Melanoma Patients from a Large Multicenter Database

A. Hauschild, F. Egberts, M. Ross, 2011, Annals of Surgical Oncology.

Pimecrolimus: a novel treatment for cetuximab-induced papulopustular eruption.

A. Hauschild, T. Schwarz, E. Eiling, 2008, Archives of dermatology.

Model soups improve performance of dermoscopic skin cancer classifiers.

Jakob Nikolas Kather, R. Maron, J. Utikal, 2022, European journal of cancer.

Short German guidelines: Basal cell carcinoma

A. Hauschild, C. Garbe, R. Kortmann, 2008, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Short German guidelines: Squamous cell carcinoma

A. Hauschild, K. Wolff, F. Bootz, 2008, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Quantification of melanoma-associated molecules in plasma/serum of melanoma patients.

A. Hauschild, E. Christophers, R. Gläser, 2001, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients.

A. Hauschild, W. Brenner, E. Henze, 2000, Anticancer research.

Immune checkpoint blockade for organ-transplant recipients with cancer: A review.

A. Hauschild, D. Schadendorf, C. Gebhardt, 2022, European journal of cancer.

Metastatic melanoma of the tongue arising from oral melanosis.

A. Hauschild, F. Egberts, P. Russo, 2008, Archives of dermatology.

[Current comments on the dermatological oncology working groups' work on high dose therapy with interferon alpha 2b].

A. Hauschild, 1999, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

Complete remission of a radio‐resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin

A. Hauschild, S. Lischner, E. Christophers, 2002, The British journal of dermatology.

Efficacy and safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): ERIVANCE BCC study update.

A. Hauschild, J. Hainsworth, L. Dirix, 2012 .

Melanoma

Carola Berking, Dirk Schadendorf, Alexander Roesch, 2018, The Lancet.

Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III.

A. Hauschild, D. Schadendorf, P. Ascierto, 2017, European journal of cancer.

The Use of Serological Tumor Markers for Malignant Melanoma

A. Hauschild, 1997 .

Cerebriform Giant Melanocytic Nevus of the Scalp: Report of Two Cases with Different Surgical Approaches

A. Hauschild, S. Lischner, A. Dunsche, 2002, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

M. Weichenthal, A. Hauschild, D. Schadendorf, 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse

M. Weichenthal, A. Hauschild, F. Egberts, 2009, Melanoma research.

S100B Protein Detection in Serum Is a Significant Prognostic Factor in Metastatic Melanoma

A. Hauschild, W. Brenner, E. Henze, 1999, Oncology.

Biomarkers in melanoma

A. Hauschild, D. Schadendorf, R. Dummer, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.

M. Weichenthal, A. Hauschild, F. Egberts, 2012, European journal of cancer.

Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients.

A. Hauschild, F. Egberts, J. Egberts, 2010, Anticancer research.

Long-Term Survival Analysis in Metastatic Melanoma: Serum S100B Is an Independent Prognostic Marker and Superior to LDH

M. Weichenthal, A. Hauschild, F. Egberts, 2008, Oncology Research and Treatment.

Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study.

A. Hauschild, E. Christophers, W. Tilgen, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long‐Term Efficacy of Subcutaneous Sweat Gland Suction Curettage for Axillary Hyperhidrosis: A Prospective Gravimetrically Controlled Study

A. Hauschild, S. Lischner, P. Russo, 2008, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

A randomized, open‐label clinical trial of tasisulam sodium versus paclitaxel as second‐line treatment in patients with metastatic melanoma

A. Hauschild, A. Arance, C. Garbe, 2014, Cancer.

In vitro Drug Sensitivity Predicts Response and Survival after Individualized Sensitivity-Directed Chemotherapy in Metastatic Melanoma: A Multicenter Phase II Trial of the Dermatologic Cooperative Oncology Group

A. Hauschild, D. Schadendorf, S. Ugurel, 2006, Clinical Cancer Research.

New Aspects in the Chemotherapy of Malignant Melanoma

A. Hauschild, 1997 .

Melanocytic nevi

A. Hauschild, F. Egberts, H. Kerl, 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

A. Hauschild, P. Ascierto, J. Larkin, 2014, The Lancet. Oncology.

Linear intraoral lesions in the sebaceous nevus syndrome.

A. Hauschild, I. Springer, E. Sherry, 2005, Journal of American Academy of Dermatology.

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

A. Hauschild, R. Dummer, G. Pentheroudakis, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Current recommendations for prevention and therapy of extravasation reactions in dermato‐oncology

A. Hauschild, K. Kähler, D. Mustroph, 2009, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors

A. Hauschild, M. Lacouture, C. Garbe, 2011, International journal of dermatology.

Melanoma risk in congenital melanocytic naevi: a systematic review

A. Hauschild, S. Krengel, T. Schäfer, 2006, The British journal of dermatology.

Neurocutaneous Melanosis: A Fatal Disease in Early Childhood

A. Hauschild, E. Livingstone, D. Spengler, 2009 .

Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial.

A. Hauschild, D. Schadendorf, S. Puig, 2017, The Lancet. Oncology.

[Cutaneous neuroendocrine carcinoma (Merkel cell carcinoma). Quality Assurance Committee of the German Society of Dermatology and the Professional Organization of German Dermatologists e. V].

A. Hauschild, C. Garbe, 1998, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

Distinction of 2 different primary Merkel cell carcinomas in 1 patient by Merkel cell polyomavirus genome analysis.

A. Hauschild, K. Kähler, J. Becker, 2010, Archives of dermatology.

Multiple skin metastases of malignant melanoma with unusual clinical and histopathologic features in an immunosuppressed patient.

A. Hauschild, F. Egberts, L. Cerroni, 2008, Journal of the American Academy of Dermatology.

PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma

A. Hauschild, D. Schadendorf, C. Chung, 2018, The New England journal of medicine.

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

A. Hauschild, D. Schadendorf, A. Gesierich, 2017, BMC Cancer.

European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention.

I. Zalaudek, A. Hauschild, J. Malvehy, 2020, European journal of cancer.

S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 2: Treatment, Prevention and Follow‐up

M. Weichenthal, A. Hauschild, A. Blum, 2019, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

Aleksandar Sekulic, Michael R Migden, Axel Hauschild, 2012, The New England journal of medicine.

Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T‐cell lymphoma

A. Hauschild, R. Dummer, M. Kaatz, 2003, Cancer.

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.

C. Berking, A. Hauschild, D. Schadendorf, 2020, The Lancet. Oncology.

Metastatic basal cell carcinoma : Prognosis dependent on anatomic site and spread of disease qq

A. Hauschild, D. Schadendorf, R. Dummer, 2014 .

Giant Basal Cell Carcinoma of the Breast Mimicking Paget’s Disease: Complete Remission after Photodynamic Therapy

A. Hauschild, K. Kähler, C. Mundhenke, 2010, Oncology Research and Treatment.

Kurzleitlinie – Malignes Melanom der Haut

A. Hauschild, D. Schadendorf, W. Stolz, 2006 .

[Brief guidelines: malignant melanoma of the skin].

A. Hauschild, D. Schadendorf, W. Stolz, 2006, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

The Oncologist® Academia–Pharma Intersect: Melanoma

A. Hauschild, J. Kirkwood, C. Garbe, 2022 .

Disseminated porokeratosis palmaris and plantaris treated with imiquimod cream to prevent malignancy.

A. Hauschild, F. Egberts, J. Jensen, 2005, Acta dermato-venereologica.

Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes

A. Hauschild, M. Mihm, S. Hirakawa, 2005, Modern Pathology.

S3‐Guideline “Diagnosis, therapy and follow‐up of melanoma” – short version

M. Weichenthal, A. Hauschild, D. Schadendorf, 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Diagnosis and Treatment of Melanoma. European Consensus ⴀbased Interdisciplinary Guideline Developed by the Guideline Subcommittee of the

A. Hauschild, J. Malvehy, H. Pehamberger, 2012 .

Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline.

Josep Malvehy, Axel Hauschild, Jean-Jacques Grob, 2010, European journal of cancer.

Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod.

A. Hauschild, S. Lischner, C. Ulrich, 2002, European journal of dermatology : EJD.

Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion

A. Hauschild, D. Schadendorf, J. Malvehy, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma

A. Hauschild, S. Puig, P. Ascierto, 2016, The oncologist.

Kurzleitlinie – Plattenepithelkarzinom der Haut

A. Hauschild, F. Bootz, C. Garbe, 2008 .

Multiple squamous cell carcinomas in junctional epidermolysis bullosa: a surgical challenge.

A. Hauschild, T. Schwarz, J. Lohmeyer, 2008, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

Brief S2k guidelines – Cutaneous squamous cell carcinoma

A. Hauschild, K. Wolff, F. Bootz, 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Brief S2k guidelines – Basal cell carcinoma of the skin

A. Hauschild, C. Garbe, R. Kortmann, 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

The Neuropeptide Alpha-Melanocyte-Stimulating Hormone Is Critically Involved in the Development of Cytotoxic CD8+ T Cells in Mice and Humans

A. Hauschild, T. Luger, S. Beissert, 2010, PloS one.

Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma

A. Hauschild, D. Schadendorf, P. Nghiem, 2017, Oncoimmunology.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

J. Utikal, A. Hauschild, D. Schadendorf, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

J. Utikal, A. Hauschild, D. Schadendorf, 2015, The Lancet.

Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors

A. Hauschild, D. Schadendorf, F. Egberts, 2011, Melanoma research.

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study

J. Utikal, A. Hauschild, D. Schadendorf, 2016, ESMO Open.

Systemic therapy for metastatic malignant melanoma – from deeply disappointing to bright future?

A. Hauschild, P. Lorigan, T. Eisen, 2008, Experimental dermatology.

Loss of leucocyte common antigen (CD45) on atypical lymphocytes in the localized but not disseminated type of Pagetoid reticulosis

A. Hauschild, W. Sterry, Axel Hauschild, 1991, The British journal of dermatology.

Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma

A. Hauschild, R. Dummer, A. Eggermont, 2012, Expert opinion on biological therapy.

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma

A. Hauschild, D. Schadendorf, R. Dummer, 2017, The New England journal of medicine.

Analysis of dermatologic events in vemurafenib-treated patients with melanoma.

A. Hauschild, D. Schadendorf, M. Lacouture, 2013, The oncologist.

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.

Dirk Schadendorf, Alessandro Testori, Axel Hauschild, 2014, The Lancet. Oncology.

Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials.

A. Hauschild, D. Schadendorf, K. Flaherty, 2014, The Lancet. Oncology.

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019.

A. Lallas, I. Zalaudek, A. Hauschild, 2020, European journal of cancer.

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019.

Giovanni Pellacani, Josep Malvehy, Axel Hauschild, 2019, European journal of cancer.

Survival of patients with advanced metastatic melanoma: The impact of novel therapies.

A. Hauschild, D. Schadendorf, S. Ugurel, 2016, European journal of cancer.

Diagnosis and treatment of melanoma . European consensus-based interdisciplinary guideline e Update 2016

Josep Malvehy, Axel Hauschild, Jean-Jacques Grob, 2016 .

A Multimarker Prognostic Assay for Primary Cutaneous Melanoma

A. Hauschild, D. Schadendorf, F. Egberts, 2009, Clinical Cancer Research.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

C. Berking, A. Hauschild, D. Schadendorf, 2013, The Lancet. Oncology.

COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma

A. Hauschild, K. Flaherty, J. Larkin, 2014 .

Efficacy of vemurafenib in BRAFV600K mutation positive melanoma disease - results from the phase III clinical study BRIM-3.

A. Hauschild, K. Flaherty, P. Ascierto, 2011 .

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.

A. Hauschild, D. Schadendorf, J. Kirkwood, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Progression of cutaneous melanoma: implications for treatment

A. Hauschild, V. Sondak, M. Mihm, 2012, Clinical & Experimental Metastasis.

Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.

A. Hauschild, S. Puig, R. Dummer, 2021, The Lancet. Oncology.

Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016.

Josep Malvehy, Axel Hauschild, Jean-Jacques Grob, 2012, European journal of cancer.

Multiple painful leiomyomas of the skin: a novel therapy with sympathicolysis?

A. Hauschild, C. Maier, E. Christophers, 1997 .

Dermatologic adverse events associated with afatinib: an oral ErbB family blocker

A. Hauschild, D. Schadendorf, M. Lacouture, 2013, Expert review of anticancer therapy.

Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)

A. Enk, A. Hauschild, P. Murawa, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized Trial

A. Hauschild, R. Dummer, J. Lear, 2020, Clinical, cosmetic and investigational dermatology.

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.

A. Hauschild, D. Schadendorf, J. Taube, 2022, The New England journal of medicine.

Short German guidelines: Merkel cell carcinoma

A. Hauschild, J. Becker, F. Bootz, 2008, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.

A. Hauschild, M. Ross, I. Puzanov, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma

A. Hauschild, U. Wehkamp, F. Egberts, 2016, Melanoma research.

Dose-Dependent Development of Depressive Symptoms During Adjuvant Interferon-α Treatment of Patients With Malignant Melanoma

A. Hauschild, C. Goldsmith, M. Schmid-Wendtner, 2010 .

Sentinel Node Dissection Delays Recurrence and Prolongs Melanoma-Related Survival: An Analysis of 673 Patients from a Single Center with Long-Term Follow-Up

A. Hauschild, R. Gutzmer, A. Kapp, 2011, Annals of Surgical Oncology.

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

A. Hauschild, D. Schadendorf, P. Ascierto, 2012, The Lancet. Oncology.

Ipilimumab in patients with cancer and the management of dermatologic adverse events.

A. Hauschild, K. Kähler, J. Wolchok, 2014, Journal of the American Academy of Dermatology.

Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials

A. Hauschild, D. Schadendorf, P. Ascierto, 2014, Journal of Translational Medicine.

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

C. Berking, A. Hauschild, D. Schadendorf, 2013, PloS one.

Management of immune-related adverse events and kinetics of response with ipilimumab.

A. Hauschild, K. Kähler, J. Weber, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

A. Hauschild, R. Dummer, M. Guggenheim, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma.

A. Hauschild, S. Ugurel, W. Guo, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

A. Hauschild, D. Schadendorf, A. Gesierich, 2017, BMC Cancer.

Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review.

A. Hauschild, P. Ascierto, H. Gogas, 2013, Critical reviews in oncology/hematology.

Surgery and radiotherapy in the treatment of cutaneous melanoma

A. Hauschild, A. Eggermont, A. Testori, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

A. Hauschild, R. Dummer, M. Guggenheim, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Prospective evaluation of follow-up in melanoma patients in Germany - results of a multicentre and longitudinal study.

J. Utikal, A. Hauschild, D. Schadendorf, 2015, European journal of cancer.

Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012.

A. Hauschild, J. Malvehy, H. Pehamberger, 2012, European journal of cancer.

[Mucous membrane melanomas of the upper aerodigestive tract. An analysis of 34 cases].

A. Hauschild, J. Werner, B. Lippert, 1997, Laryngo- rhino- otologie.

Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives

A. Hauschild, C. Robert, O. Michielin, 2020, British Journal of Cancer.

Depressive Mood Changes and Psychiatric Symptoms During 12-month Low-dose Interferon-α Treatment in Patients With Malignant Melanoma: Results From the Multicenter DeCOG Trial

A. Hauschild, F. Egberts, T. Vogt, 2010, Journal of immunotherapy.

Quality of life in patients receiving high-dose interferon alfa-2b after resected high-risk melanoma.

M. Weichenthal, A. Hauschild, U. Trefzer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Practical guidelines for the management of interferon‐α‐2b side effects in patients receiving adjuvant treatment for melanoma

A. Hauschild, J. Kirkwood, A. Testori, 2008, Cancer.

Diagnostic and therapeutic procedures for management of melanoma during pregnancy: risks for the fetus?

A. Hauschild, F. Egberts, S. Lischner, 2006, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician

A. Enk, A. Hauschild, J. Becker, 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Giant naevoid syringocystadenoma papilliferum.

A. Hauschild, K. Kaehler, B. Lange‐Asschenfeldt, 2005, Acta dermato-venereologica.

Melanomas of unknown primary frequently harbor TERT-promoter mutations

Sandra Krüger, Axel Hauschild, Jochen Haag, 2014, Melanoma research.

Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.

A. Hauschild, D. Schadendorf, S. Ugurel, 2017, European journal of cancer.

Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.

A. Hauschild, W. Miller, P. Rutkowski, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Intermittent BRAF‐inhibitor therapy is a feasible option: report of a patient with metastatic melanoma

A. Hauschild, M. Alter, R. Gutzmer, 2014, The British journal of dermatology.

Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice.

A. Hauschild, V. Sondak, P. Chapman, 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

H. Kong, A. Hauschild, M. Atkins, 2008, The oncologist.

Cutaneous melanoma: A model to study cancer metastasis

A. Hauschild, D. Schadendorf, J. Gershenwald, 2011, Journal of surgical oncology.

BIOMARKERS IN MELANOMA — NEW FRONTIERS TO PREDICT THE OUTCOMES OF PATIENTS ?

A. Hauschild, D. Schadendorf, J. Gershenwald, 2011 .

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial

C. Berking, A. Hauschild, D. Schadendorf, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis

K. Buder-Bakhaya, A. Hauschild, D. Schadendorf, 2022, European Journal of Cancer.

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

A. Hauschild, D. Schadendorf, I. Lowy, 2020, Journal for immunotherapy of cancer.

KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma.

Charles H. Yoon, A. Hauschild, James R. Anderson, 2019, Future oncology.

A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients

A. Hauschild, J. Becker, P. Ascierto, 2019, Cancer Immunology, Immunotherapy.

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma

A. Hauschild, I. Puzanov, C. Garbe, 2019, British Journal of Cancer.

Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial.

C. Berking, A. Hauschild, D. Schadendorf, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Diabetes mellitus in cancer patients treated with combination interleukin 2 and alpha-interferon.

A. Hauschild, R. Figlin, E. Christophers, 1995, Cancer biotherapy.

Paraneoplastic leukemoid reaction and rapid progression in a patient with malignant melanoma: Establishment of KT293, A novel G-CSF-secreting melanoma cell line

A. Hauschild, H. Kalthoff, B. Schniewind, 2005, Cancer biology & therapy.

787O Adjuvant immunotherapy with nivolumab (NIVO) versus observation in completely resected Merkel cell carcinoma (MCC): Disease-free survival (DFS) results from ADMEC-O, a randomized, open-label phase II trial

A. Hauschild, S. Haferkamp, D. Schadendorf, 2022, Annals of Oncology.

Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

A. Enk, J. Utikal, A. Hauschild, 2015, PloS one.

Melanoma in 2013: Melanoma—the run of success continues

Dirk Schadendorf, Axel Hauschild, A. Hauschild, 2014, Nature Reviews Clinical Oncology.

Meeting report from the “ Melanoma Research : a bridge from Naples to the World . Napoli , December 5 th – 6 th 2011 ”

A. Hauschild, K. Flaherty, P. Ascierto, 2012 .

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

A. Hauschild, K. Flaherty, P. Ascierto, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.

A. Hauschild, D. Schadendorf, K. Flaherty, 2020, The Lancet. Oncology.

30 years German Dermatologic Cooperative Oncology Group (DeCOG)

C. Berking, A. Hauschild, D. Schadendorf, 2021, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

J. Utikal, C. Berking, A. Hauschild, 2020, The Lancet.

Malignant Melanoma and HIV Infection – Aggressive Course despite Immune Reconstitution

M. Weichenthal, A. Hauschild, C. Hoffmann, 2004, Oncology Research and Treatment.

Does Basal Cell Carcinoma Belong to the Spectrum of Sorafenib-Induced Epithelial Skin Cancers?

A. Hauschild, R. Gutzmer, A. Degen, 2010, Dermatology.

Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real‐world conditions in Germany – The non‐interventional study NIELS

C. Berking, A. Hauschild, S. Haferkamp, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study

A. Hauschild, P. Ascierto, R. Dummer, 2018, European Journal of Dermatology.

Melanoma and Cutaneous Malignancies Characterization andManagement of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma

A. Hauschild, S. Puig, P. Ascierto, 2016 .

Primary analysis of phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC).

C. Berking, A. Hauschild, D. Schadendorf, 2019, Journal of Clinical Oncology.

Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up.

A. Hauschild, I. Lowy, R. Gutzmer, 2019, Journal of Clinical Oncology.

1066P Extended-dose cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Primary analysis of phase II results

A. Hauschild, D. Schadendorf, N. Basset-Seguin, 2021, Annals of Oncology.

Quality‐of‐life analysis with intermittent vismodegib regimens in patients with multiple basal cell carcinomas: patient‐reported outcomes from the MIKIE study

A. Hauschild, D. Schadendorf, S. Puig, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Interim Analysis of Phase 2 Results for Cemiplimab in Patients with Metastatic Basal Cell Carcinoma (mBCC) who Progressed on or are Intolerant to Hedgehog Inhibitors (HHIs)

A. Hauschild, I. Lowy, K. Lewis, 2021 .

428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)

A. Hauschild, K. Peris, G. Yancopoulos, 2020 .

Impact of treatment breaks on vismodegib patient outcomes: Exploratory analysis of the STEVIE study.

A. Hauschild, P. Ascierto, R. Dummer, 2015 .

Vismodegib for advanced basal cell carcinoma: Duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression.

A. Hauschild, A. Gesierich, J. Hainsworth, 2014 .

[Merkel cell carcinoma: follow-up of 10 patients. Current diagnosis and therapy].

A. Hauschild, E. Christophers, J. Roewert, 1997, Archiv fuer Klinische Chirurgie.

Integrating first-line treatment options into clinical practice: what’s new in advanced melanoma?

A. Hauschild, D. Schadendorf, P. Ascierto, 2015, Melanoma research.

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.

A. Hauschild, D. Schadendorf, K. Flaherty, 2015, The Lancet. Oncology.

Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts.

Jakob Nikolas Kather, Roman C. Maron, H. Haenssle, 2021, European journal of cancer.

Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts

J. Utikal, A. Hauschild, D. Schadendorf, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Distinct clinicopathological and prognostic features of thin nodular primary melanomas: an international study from 17 centers.

I. Zalaudek, A. Hauschild, F. Egberts, 2019, Journal of the National Cancer Institute.

Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study

A. Hauschild, P. Ascierto, J. Larkin, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety

R Hofmann-Wellenhof, R. Hofmann-Wellenhof, J. Paoli, 2014, The British journal of dermatology.

Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma.

A. Hauschild, D. Schadendorf, W. Stolz, 2007, Melanoma research.

Photodynamic therapy simplified: nonprepared, moderate‐grade actinic keratosis lesions respond equally well to 5‐aminolaevulinic acid patch photodynamic therapy as do mild lesions

A. Hauschild, A. Moor, C. Surber, 2015, British Journal of Dermatology.

Long‐term follow‐up of photodynamic therapy with a self‐adhesive 5‐aminolaevulinic acid patch: 12 months data

A. Hauschild, A. Moor, U. Reinhold, 2010, The British journal of dermatology.

Optimization of photodynamic therapy with a novel self‐adhesive 5‐aminolaevulinic acid patch: results of two randomized controlled phase III studies

A. Hauschild, A. Moor, U. Reinhold, 2009, The British journal of dermatology.

MIKIE: A randomized, double-blind, regimen-controlled, phase II, multicenter study to assess the efficacy and safety of two different vismodegib regimens in patients with multiple basal cell carcinomas.

A. Hauschild, D. Schadendorf, B. Dréno, 2014 .

Actual practice of melanoma follow‐up and treatment in Germany: results of a prospective, longitudinal cohort study

A. Hauschild, D. Schadendorf, K. Kähler, 2015, The British journal of dermatology.

Electrochemotherapy in symptomatic melanoma skin metastases: intraindividual comparison with conventional surgery.

A. Hauschild, F. Egberts, K. Kaehler, 2010, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macro-metastatic nodes: EADO trial.

A. Hauschild, H. Pehamberger, M. Landthaler, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM).

A. Hauschild, A. Eggermont, S. O’Day, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis.

M. Weichenthal, A. Hauschild, R. Dummer, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma.

A. Hauschild, K. Hellstrand, M. Middleton, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.

M. Weichenthal, A. Hauschild, H. Pehamberger, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)

A. Hauschild, S. Ugurel, W. Stolz, 2001, British Journal of Cancer.

Recent aspects of medical care of malignant melanoma

A. Hauschild, P. Terheyden, W. Tilgen, 2008, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

New promises in the adjuvant, and palliative treatment of melanoma.

A. Hauschild, D. Schadendorf, K. Kähler, 2007, Cancer treatment and research.

Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low‐dose interferon alpha

A. Hauschild, R. Gutzmer, A. Kapp, 2007, International journal of cancer.

Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.

A. Hauschild, D. Schadendorf, S. Ugurel, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

A. Hauschild, R. Dummer, G. Pentheroudakis, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Sorafenib, a Multikinase Inhibitor: Results from Clinical Trials in Melanoma Patients

A. Hauschild, K. Kähler, F. Egberts, 2009 .

Metastatic Melanoma: Scientific Rationale for Sorafenib Treatment and Clinical Results

A. Hauschild, K. Kähler, F. Egberts, 2008, Oncology Research and Treatment.

Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up.

A. Hauschild, D. Schadendorf, I. Lowy, 2020 .

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system.

A. Hauschild, P. Ascierto, J. Larkin, 2019, European journal of cancer.

Treatment of melanoma.

A. Hauschild, C. Garbe, P. Terheyden, 2008, Deutsches Arzteblatt international.

Histamine dihydrochloride administered with interleukin-2 increases survival duration in patients with ocular melanoma with liver metastases

A. Hauschild, S. O’Day, J. Glaspy, 2001 .

[Adjuvant drug therapy of malignant melanoma. Current knowledge and multi-center studies in German-speaking countries].

A. Hauschild, M. Volkenandt, C. Garbe, 2000, Deutsche medizinische Wochenschrift.

Combined interferon-α and interleukin-2 as adjuvant treatment for melanoma

A. Hauschild, R. Dummer, G. Burg, 1998, The Lancet.

Combined interferon-alpha and interleukin-2 as adjuvant treatment for melanoma.

A. Hauschild, R. Dummer, G. Burg, 1998, Lancet.

LBA35OVERALL SURVIVAL AND BIOMARKER RESULTS FROM A PHASE 2 STUDY OF MEK1/2 INHIBITOR BINIMETINIB (MEK162) IN PATIENTS WITH ADVANCED NRAS-MUTANT MELANOMA

C. Berking, A. Hauschild, D. Schadendorf, 2014 .

Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial

A. Hauschild, U. Reinhold, U. Pichlmeier, 2003, Melanoma research.

Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

A. Hauschild, D. Schadendorf, A. Gesierich, 2019, BMC Cancer.

Staging of cutaneous melanoma

A. Hauschild, A. Eggermont, A. Buzaid, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Photodynamic therapy for actinic keratoses: procedure matters?

A. Hauschild, 2012, The British journal of dermatology.

Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.

A. Enk, M. Weichenthal, A. Hauschild, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Side-effects of interferon therapy in their management].

A. Hauschild, E. Christophers, H. Hinrichsen, 2000, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019.

A. Hauschild, D. Schadendorf, J. Becker, 2020, European journal of cancer.

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022.

A. Lallas, I. Zalaudek, A. Hauschild, 2022, European journal of cancer.

Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

A. Hauschild, D. Schadendorf, A. Gesierich, 2019, BMC Cancer.

Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up

A. Hauschild, D. Schadendorf, I. Lowy, 2020 .

Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab.

M. Weichenthal, A. Hauschild, K. Kähler, 2017, European journal of cancer.

Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.

A. Hauschild, R. Dummer, K. Peris, 2018, European journal of cancer.

Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.

Dirk Schadendorf, Axel Hauschild, Reinhard Dummer, 2014, European journal of cancer.

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.

A. Hauschild, D. Schadendorf, F. Egberts, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations.

C. Berking, A. Hauschild, D. Schadendorf, 2012 .

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

A. Hauschild, G. Linette, J. Kirkwood, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF‐200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy

C. Berking, A. Hauschild, H. Kurzen, 2018, The British journal of dermatology.

Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients.

C. Berking, A. Hauschild, K. Kähler, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha‐2b in metastatic melanoma (phase II DeCOG trial)

Axel Hauschild, Michael Weichenthal, Claus Garbe, 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Sentinel node biopsy in melanoma

A. Hauschild, E. Christophers, 2001, Virchows Archiv.

clinical practice guidelines Melanoma : ESMO Clinical Practice Guidelines for diagnosis , treatment and follow-up

A. Hauschild, R. Dummer, M. Guggenheim, 2010 .

Clinicopathologic prognostic markers of survival: an analysis of 259 patients with malignant melanoma ≥1 mm

M. Weichenthal, A. Hauschild, F. Egberts, 2009, Tumor Biology.

[Safety margins in the excision of primary malignant melanoma. Proposals based on controlled clinical trials].

A. Hauschild, S. Lischner, E. Christophers, 2001, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group

A. Hauschild, D. Schadendorf, S. Wagner, 2008, Melanoma research.

Combined treatment with pegylated interferon–α‐2a and dacarbazine in patients with advanced metastatic melanoma

A. Hauschild, D. Schadendorf, S. Ugurel, 2008, Cancer.

Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).

A. Hauschild, D. Schadendorf, S. Ugurel, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Reply to K.S. Wilson et al.

A. Hauschild, A. Ribas, R. Kefford, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.

A. Hauschild, H. Pehamberger, M. Landthaler, 2013, European journal of cancer.

Immunotherapy of distant metastatic disease

A. Hauschild, D. Schadendorf, A. Eggermont, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Small molecules and targeted therapies in distant metastatic disease

A. Hauschild, D. Schadendorf, R. Dummer, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts).

A. Hauschild, P. Ascierto, R. Dummer, 2016 .

DERMA phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in patients with MAGE-A3-positive resected stage III melanoma.

A. Hauschild, D. Schadendorf, J. Kirkwood, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.

Dirk Schadendorf, Axel Hauschild, Antoni Ribas, 2019, European journal of cancer.

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM

A. Hauschild, K. Flaherty, P. Ascierto, 2019, British Journal of Cancer.

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.

M. Weichenthal, A. Hauschild, D. Schadendorf, 2018, European journal of cancer.

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.

A. Hauschild, A. Testori, M. Del Vecchio, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials

A. Hauschild, D. Schadendorf, K. Flaherty, 2015, Clinical Cancer Research.

Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma

A. Hauschild, P. Ascierto, A. Eggermont, 2015, American journal of therapeutics.

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?

A. Hauschild, K. Kähler, H. Moch, 2015, PloS one.

Algorithm for the management of metastatic cutaneous melanoma.

A. Hauschild, M. Atkins, A. Buzaid, 2014, Chinese clinical oncology.

Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy.

A. Hauschild, Hiba Asper, R. Gutzmer, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.

A. Hauschild, D. Schadendorf, R. Dummer, 2019, The Lancet. Oncology.

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis

A. Hauschild, D. Schadendorf, R. Sullivan, 2020, British Journal of Cancer.

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.

A. Hauschild, S. Puig, J. Goeman, 2018, The Lancet. Oncology.

Artificial Intelligence and Its Effect on Dermatologists’ Accuracy in Dermoscopic Melanoma Image Classification: Web-Based Survey Study (Preprint)

R. Maron, M. Weichenthal, J. Utikal, 2020 .

Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data.

Carola Berking, Wiebke Sondermann, Dirk Schadendorf, 2019, European journal of cancer.

Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task.

Achim Hekler, Carola Berking, Dirk Schadendorf, 2019, European journal of cancer.

A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task.

Achim Hekler, Carola Berking, Dirk Schadendorf, 2019, European journal of cancer.

Comparing artificial intelligence algorithms to 157 German dermatologists: the melanoma classification benchmark.

Achim Hekler, Carola Berking, Dirk Schadendorf, 2019, European journal of cancer.

More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.

I. Zalaudek, A. Hauschild, R. Dummer, 2017, European journal of cancer.

Treatment Algorithms in Stage IV Melanoma

A. Hauschild, D. Schadendorf, R. Dummer, 2015, American journal of therapeutics.

3342 Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma (BCC) treated with vismodegib in the STEVIE study

A. Hauschild, P. Ascierto, R. Dummer, 2015 .

CO14. A pivotal study evaluating efficacy and safety of the hedgehog pathway inhibitor (HPI) vismodegib (GDC-0449) in patients with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC)

A. Hauschild, S. Arron, C. Rudin, 2011 .

Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries

R. Karls, A. Lallas, J. Paoli, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

The evolving field of Dermato‐oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV–UEMS and EORTC Cutaneous Lymphoma Task Force

A. Enk, M. Arenbergerova, A. Lallas, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Comment on 'Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines'.

I. Zalaudek, A. Hauschild, J. Malvehy, 2020, European journal of cancer.

Metastatic basal cell carcinoma: Differences in survival by site of spread.

A. Hauschild, J. Hou, H. Yue, 2012 .

Efficacy of interferon alpha 2a in 18 versus 60 months of treatment in patients with primary melanoma of ≥ 1.5 mm tumor thickness: A randomized phase III DeCOG trial

M. Weichenthal, A. Hauschild, T. Vogt, 2008 .

A randomized, multi-national, non-inferiority, phase III trial to evaluate the safety and efficacy of BF-200 ALA gel versus MAL cream in the treatment of non-aggressive basal cell carcinoma with photodynamic therapy (PDT)

C. Berking, A. Hauschild, H. Kurzen, 2018 .

Novel DNA methylation markers with potential prognostic relevance in advanced malignant melanoma identified using COBRA assays

Axel Hauschild, Hannes-Friedrich Ulbrich, A. Hauschild, 2015, Melanoma research.

An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma

A. Hauschild, D. Schadendorf, R. Dummer, 2008, Clinical Cancer Research.

Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations

A. Hauschild, D. Schadendorf, M. Herlyn, 2015, Experimental dermatology.

Treatment of Actinic Cheilitis Using Photodynamic Therapy with Methylaminolevulinate: Report of Three Cases

A. Hauschild, F. Egberts, S. Lischner, 2005, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma

A. Hauschild, D. Schadendorf, D. Castro, 2003, Melanoma research.

Prospective randomized multicenter trial on the outpatient use of subcutaneous interleukin 2 and interferon ??2b in high risk melanoma patients: 401

A. Hauschild, R. Dummer, G. Burg, 1997 .

Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas.

A. Hauschild, F. Egberts, C. Röcken, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Tyrosinase Fails as an Early Melanoma Progression Marker

A. Hauschild, E. Christophers, R. Gläser, 1996 .

Individualized therapy of disseminated cancer using malignant melanoma as a model

A. Hauschild, K. Kähler, F. Egberts, 2006, Cancer and Metastasis Reviews.

Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany

M. Weichenthal, J. Utikal, C. Berking, 2022, Cancers.

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial

J. Utikal, C. Berking, A. Hauschild, 2022, The Lancet.

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.

A. Hauschild, S. Puig, R. Fisher, 2021, European journal of cancer.

Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600–Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials

A. Hauschild, K. Flaherty, P. Ascierto, 2018, JAMA oncology.

Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial.

A. Hauschild, D. Schadendorf, R. Dummer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant Melanoma Therapy

A. Hauschild, E. Stockfleth, 1997 .

A multicentre study of naevus‐associated melanoma vs. de novo melanoma, tumour thickness and body site differences *

I. Zalaudek, A. Hauschild, F. Egberts, 2021, The British journal of dermatology.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

J. Utikal, A. Hauschild, D. Schadendorf, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, Ludmila V. Danilova, David C. Smith, 2016, Journal of Translational Medicine.

Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma.

A. Hauschild, D. Schadendorf, K. Flaherty, 2019, Journal of Clinical Oncology.

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.

A. Hauschild, D. Schadendorf, K. Flaherty, 2017, European journal of cancer.

A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma

A. Hauschild, J. Kirkwood, P. Hersey, 2008 .

Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial.

A. Hauschild, D. Schadendorf, R. Dummer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

A. Hauschild, D. Schadendorf, R. Dummer, 2014 .

Varying Mutational Alterations in Multiple Primary Melanomas.

A. Hauschild, A. Bohne, F. Egberts, 2016, The Journal of molecular diagnostics : JMD.

29 Serum S100β detection predicts therapeutic outcome in metastatic melanoma

A. Hauschild, W. Brenner, E. Henze, 1997 .

Effectiveness and Tolerability of Ipilimumab: Experiences From 198 Patients Included in a Named-Patient Program in Various Daily-Practice Settings and Multiple Institutions

A. Hauschild, K. Kähler, C. Garbe, 2014, Journal of immunotherapy.

Use of monoclonal antibodies (UCHL1, Ki-B3) against T and B cell antigens in routine paraffin-embedded skin biopsy specimens.

A. Hauschild, W. Sterry, Wolfram Sterry, 1989, Journal of the American Academy of Dermatology.

Suppressed thyroid-stimulating hormone secretion in patients treated with interleukin-2 and interferon-α2b for metastatic melanoma

A. Hauschild, S. Lange, U. Fölsch, 1994, The clinical investigator.

Robustness of convolutional neural networks in recognition of pigmented skin lesions.

Jakob Nikolas Kather, R. Maron, J. Utikal, 2021, European journal of cancer.

Meeting report: consensus from the first and second Global Workshops in Melanoma November 19–20, 2008

A. Hauschild, D. Schadendorf, A. Halpern, 2009, Pigment cell & melanoma research.

Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma.

A. Hauschild, C. Goldsmith, M. Schmid-Wendtner, 2010, Psychosomatics.

Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials

A. Hauschild, K. Flaherty, P. Ascierto, 2020, Journal of Translational Medicine.

Willingness to pay for a cure of low-risk melanoma patients in Germany

J. Utikal, A. Hauschild, D. Schadendorf, 2018, PloS one.

Response to a costly revolution for a subgroup of patients with metastatic melanoma

A. Hauschild, 2013 .

BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes.

A. Hauschild, D. Schadendorf, P. Ascierto, 2022, European journal of cancer.

Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase

A. Hauschild, B. Schilling, V. Glutsch, 2020, Acta dermato-venereologica.

LBA4_PRCOMBI-V: A RANDOMISED, OPEN-LABEL, PHASE III STUDY COMPARING THE COMBINATION OF DABRAFENIB (D) AND TRAMETINIB (T) WITH VEMURAFENIB (V) AS FIRST-LINE THERAPY IN PATIENTS (PTS) WITH UNRESECTABLE OR METASTATIC BRAF V600E/K MUTATION-POSITIVE CUTANEOUS MELANOMA

A. Hauschild, D. Schadendorf, R. Dummer, 2014 .

Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification.

Jakob Nikolas Kather, J. Utikal, A. Hekler, 2021, European journal of cancer.

Molecularly targeted therapy for melanoma

A. Hauschild, J. Becker, R. Dummer, 2006, Cancer.

Explainable artificial intelligence in skin cancer recognition: A systematic review.

Jakob Nikolas Kather, R. Maron, J. Utikal, 2022, European journal of cancer.

22 Final results of two randomized adjuvant trials of DeCOG

A. Hauschild, W. Stolz, U. Reinhold, 2004 .

A benchmark for neural network robustness in skin cancer classification.

Jakob Nikolas Kather, R. Maron, J. Utikal, 2021, European Journal of Cancer.

Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumours.

Jakob Nikolas Kather, M. Weichenthal, J. Utikal, 2021, European journal of cancer.

Artificial Intelligence in Skin Cancer Diagnostics: The Patients' Perspective

R. Maron, J. Utikal, A. Hekler, 2020, Frontiers in Medicine.

Superior skin cancer classification by the combination of human and artificial intelligence.

Tim Holland-Letz, Achim Hekler, Carola Berking, 2019, European journal of cancer.

Integrating Patient Data Into Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review

Jakob Nikolas Kather, R. Maron, J. Utikal, 2021, Journal of medical Internet research.

The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022

A. Hauschild, P. Ascierto, J. Sosman, 2023, Journal of Translational Medicine.

Feasibility of assessing utilities with a single-item standard gamble questionnaire in patients with melanoma

A. Hauschild, K. Kähler, Tobias Wagner, 2021, Journal of Patient-Reported Outcomes.

Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E mutated melanoma: an update from the phase III randomized, open-label, multicenter BRIM3 trial

A. Hauschild, D. Schadendorf, K. Flaherty, 2011 .

Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma

J. Utikal, C. Berking, A. Hauschild, 2015, Journal of Translational Medicine.

Progression of cutaneous melanoma: implications for treatment

A. Hauschild, V. Sondak, M. Mihm, 2012, Clinical & Experimental Metastasis.

Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib.

A. Hauschild, K. Flaherty, P. Ascierto, 2019, European journal of cancer.

Imiquimod: Wirkmechanismen und Therapieindikationen

A. Hauschild, E. Stockfleth, S. Lischner, 2003 .

Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED)

A. Hauschild, D. Schadendorf, C. Garbe, 2019, Annals of Oncology.

Analysis of serum biomarkers and tumor genetic alterations from a phase II study of lenvatinib in patients with advanced BRAF wild-type melanoma.

A. Hauschild, K. Flaherty, C. Andresen, 2013 .

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition

C. Berking, A. Hauschild, D. Schadendorf, 2021, Journal for ImmunoTherapy of Cancer.

Complete response of advanced cutaneous squamous cell and basal cell carcinomas with sequential cemiplimab and sonidegib therapy

M. Weichenthal, A. Hauschild, J. Weis, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma.

A. Hauschild, J. Hainsworth, K. Flaherty, 2013 .

Hidden Variables in Deep Learning Digital Pathology and Their Potential to Cause Batch Effects: Prediction Model Study

Jakob Nikolas Kather, R. Maron, M. Weichenthal, 2021, Journal of medical Internet research.

Using Multiple Dermoscopic Photographs of One Lesion Improves Melanoma Classification via Deep Learning: A Prognostic Diagnostic Accuracy Study

Jakob Nikolas Kather, R. Maron, J. Utikal, 2023, ArXiv.

Expanded access programmes: patient interests versus clinical trial integrity.

A. Hauschild, D. Schadendorf, V. Sondak, 2015, The Lancet. Oncology.

Kissing melanoma or kissing nevus of the penis?

A. Hauschild, F. Egberts, J. Egberts, 2007, Urology.

Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world Dermatologic Cooperative Oncology Group study

A. Hauschild, D. Schadendorf, K. Kähler, 2023, European Journal of Cancer.

Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

J. Utikal, A. Hauschild, S. Haferkamp, 2023, The Lancet.

Bexarotene and systemic disease progression in CTCL?

M. Weichenthal, A. Hauschild, R. Dummer, 2006, Journal of the American Academy of Dermatology.

Characteristics of Patients With a Complete Response Treated With Dabrafenib + Trametinib Combination Therapy: Findings From Pooled COMBI-d and COMBI-v 5-Year Analysis

A. Hauschild, D. Schadendorf, K. Flaherty, 2020 .

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

J. Utikal, A. Hauschild, D. Schadendorf, 2019 .

Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma.

A. Hauschild, M. Ross, I. Puzanov, 2017 .

Abstract S02-01: Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI)

A. Hauschild, P. Ascierto, P. Queirolo, 2020 .

Vemurafenlb Improves Overall Survival Compared to Dacarbazlne In Advanced BRAFV600E-mutated Melanoma: Updated Survival Results From a Phase III Randomised, Open-label, Multlcentre Trial

A. Hauschild, K. Flaherty, P. Ascierto, 2011 .

Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors.

A. Hauschild, P. Ascierto, R. Dummer, 2023, Critical reviews in oncology/hematology.

European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023.

A. Lallas, I. Zalaudek, A. Hauschild, 2023, European journal of cancer.

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023.

A. Lallas, I. Zalaudek, A. Hauschild, 2023, European journal of cancer.

[Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].

A. Hauschild, S. Lischner, F. Rosien, 2002, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

1105PVEMURAFENIB FOR BRAF V600 MUTATED ADVANCED MELANOMA: RESULTS OF TREATMENT BEYOND PROGRESSION.

Y. S. Kim, Su Jin Lee, J. Utikal, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial

A. Hauschild, C. Garbe, P. Friedlander, 2023, Journal for ImmunoTherapy of Cancer.

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023.

A. Lallas, I. Zalaudek, A. Hauschild, 2023, European journal of cancer.

Response to: Comment on 'Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines'.

I. Zalaudek, A. Hauschild, J. Malvehy, 2020, European journal of cancer.

Multiple myeloma first presenting as cutaneous plasmacytoma.

A. Hauschild, T. Haferlach, E. Christophers, 1996, Journal of the American Academy of Dermatology.

Future Perspectives in melanoma research. Meeting report from the Research: a to

A. Hauschild, K. Flaherty, P. Ascierto, 2012 .

German S3 guideline “actinic keratosis and cutaneous squamous cell carcinoma” – long version of the update 2023

M. Weichenthal, A. Hauschild, M. Flaig, 2023, EJC Skin Cancer.

Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp.

A. Hauschild, D. Schadendorf, L. Heinzerling, 2023, European journal of cancer.

Diagnosis and treatment of basal cell carcinoma European consensus-based interdisciplinary guidelines Association of Dermato-Oncology (EADO), European Organization for Research and Treatment of Cancer

I. Zalaudek, A. Hauschild, J. Malvehy, 2019 .

Systematic review of medical treatment in melanoma: current status and future prospects.

A. Hauschild, J. Kirkwood, C. Garbe, 2011, The oncologist.

Neoadjuvant immunotherapy for melanoma is now ready for clinical practice

A. Hauschild, D. Schadendorf, P. Ascierto, 2023, Nature Medicine.

Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma.

A. Hauschild, C. Blank, P. Rutkowski, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Break-MB: a phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets)

A. Hauschild, D. Schadendorf, P. Ascierto, 2012 .

Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma.

A. Hauschild, K. Flaherty, P. Ascierto, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Final analysis of a randomized phase III DeCOG-trial (NCT00226408).

A. Enk, M. Weichenthal, A. Hauschild, 2008 .

Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology.

A. Hauschild, D. Schadendorf, P. Ascierto, 2019, European journal of cancer.

767O TREATMENT OF PATIENTS WITH ADVANCED REFRACTORY OR RELAPSED MELANOMA IN A PHASE II STUDY OF TREMELIMUMAB (CP-675,206), AN ANTI-CTLA4 MONOCLONAL ANTIBODY

A. Hauschild, D. Schadendorf, H. Pehamberger, 2008 .

Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study.

M. Weichenthal, A. Hauschild, D. Schadendorf, 2017 .

Impact of gene expression profiles on clinical predictors of survival in patients (pts) with BRAFV600-mutated metastatic melanoma (mM).

A. Hauschild, K. Flaherty, P. Ascierto, 2017 .

Hauschild A, Grob JJ, Demidov LV et al.Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365

A. Hauschild, C. Blank, W. Miller, 2012 .

Vismodegib, a Hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study interim analysis in 300 patients.

A. Hauschild, P. Ascierto, J. Grob, 2013 .

An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma

A. Hauschild, D. Schadendorf, R. Dummer, 2008, Clinical Cancer Research.

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials

A. Hauschild, D. Schadendorf, K. Flaherty, 2015, Clinical Cancer Research.

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

A. Hauschild, C. Blank, W. Miller, 2012, The Lancet.

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

A. Hauschild, D. Schadendorf, P. Ascierto, 2012, The Lancet. Oncology.

Improved overall survival in melanoma with combined dabrafenib and trametinib.

A. Hauschild, D. Schadendorf, K. Flaherty, 2015, The New England journal of medicine.

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

A. Hauschild, G. Linette, J. Kirkwood, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma

A. Hauschild, J. Kirkwood, P. Hersey, 2010, Clinical Cancer Research.

Hautreaktionen unter EGFR-Inhibitoren – Klinik und Management

A. Hauschild, A. Wollenberg, T. Dirschka, 2010, Deutsche medizinische Wochenschrift.

[Protocol for optimal therapy of malignant melanoma in the metastatic stage by the Dermatologic Oncology Working Group].

A. Hauschild, 1996, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

Treatment and side effect management of CTLA‐4 antibody therapy in metastatic melanoma

A. Hauschild, K. Kähler, 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

A. Hauschild, F. Egberts, A. Heinz, 2011, Journal of immunotherapy.

Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG

M. Weichenthal, A. Hauschild, S. Haferkamp, 2023, Journal for ImmunoTherapy of Cancer.

A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task.

A. Enk, Therezia Bokor-Billmann, K. Buder-Bakhaya, 2019, European journal of cancer.

Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies.

A. Hauschild, C. Rudin, J. Hainsworth, 2014 .

Effectiveness and Tolerability of Ipilimumab: Experiences From 198 Patients Included in a Named-Patient Program in Various Daily-Practice Settings and Multiple Institutions

A. Hauschild, K. Kähler, C. Garbe, 2014, Journal of immunotherapy.

Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers.

A. Hauschild, D. Schadendorf, R. Carvajal, 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.